Express Pharma

DRL launches Paricalcitol injection in the US market

1

It is the first ANDA product launched in the US market

Dr. Reddy’s Laboratories (DRL) recently  launched Paricalcitol injection, USP, in 2 mcg, 5 mcg, 10 mcg. It is a therapeutic equivalent generic version of Zemplar  (paricalcitol) Injection in the US market approved by the US Food & Drug Administration. It is the first ANDA product launched in the US market.

The Zemplar brand and generic had US sales of approximately $ 22.5 million MAT for the recent twelve months ending in July 2016 according to IMS Health.

EP News Bureau

Comments are closed.